» Articles » PMID: 23265140

Case-control Study of HLA-G Promoter Methylation Status, HPV Infection and Cervical Neoplasia in Curitiba, Brazil: a Pilot Analysis

Abstract

Background: The causal association between persistent human papillomavirus (HPV) infection and cervical cancer has been established, but the mechanisms that favor HPV persistence in cervical cells are still unknown. The diminished capability of the immune system to control and resolve HPV infection is one of several hypotheses. The tolerogenic protein HLA-G has shown aberrant expression in a variety of cancers, which has been suggested as a mechanism for tumor escape from immunosurveillance. In the present study we evaluate the role of epigenetic modification (promoter de-methylation) of the HLA-G gene on susceptibility to HPV infection and development of high-grade cervical lesions.

Methods: A case-control study was carried out in Curitiba, Brazil, between February and June 2010. A total of 789 women aged 15-47 years were recruited: 510 controls with normal cervical cytology, and 279 cases with histologically confirmed cervical intraepithelial neoplasia grade 2 (CIN2, N = 150) or grade 3 (CIN3, N = 129). All women were administered a questionnaire by interview, which collected information on demographic and lifestyle factors, and a cervical sample was collected. HPV DNA detection was performed by GP5+/GP6+ primer-mediated PCR. HPV-positive samples were genotyped by multiplex PCR. A pilot analysis of HLA-G promoter methylation was carried out in a subset of the study population (96 cases and 76 controls) by pyrosequencing. HLA-G methylation and HPV infection status of cases and controls were compared, and confounding factors were computed by t Student and non-parametric Wilcoxon tests. Comparison of HLA-G methylation between cases and controls was assessed by the Bonferroni correction. The association of HLA-G methylation with CIN2/3 was evaluated by logistic regression.

Results: HPV prevalence was 19.6% in controls and 94.3% in CIN2/3 cases. HPV16, 31, 33, 35 and 18 were the most prevalent types. Methylation analysis of seven CpGs in the HLA-G promoter did not reveal any spontaneous de-methylation events in CIN2/3 cases (mean proportion of methylation: 75.8%) with respect to controls (mean 73.7%; odds ratio 1.01, 95% confidence interval 0.96, 1.07).

Conclusions: This study did not support the hypothesis that spontaneous de-methylation events in the HLA-G promoter play a primary role in promoting escape from immunosurveillance in the development of precancerous cervical lesions.

Citing Articles

Role of HLA-G in Viral Infections.

Jasinski-Bergner S, Schmiedel D, Mandelboim O, Seliger B Front Immunol. 2022; 13:826074.

PMID: 35237271 PMC: 8882596. DOI: 10.3389/fimmu.2022.826074.


The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.

Xu H, Yan W, Lin A Front Immunol. 2020; 11:1349.

PMID: 32670296 PMC: 7330167. DOI: 10.3389/fimmu.2020.01349.


Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and meta-analysis.

Colpani V, Soares Falcetta F, Bidinotto A, Kops N, Falavigna M, Hammes L PLoS One. 2020; 15(2):e0229154.

PMID: 32084177 PMC: 7034815. DOI: 10.1371/journal.pone.0229154.


HLA-G Molecules in Autoimmune Diseases and Infections.

Rizzo R, Bortolotti D, Bolzani S, Fainardi E Front Immunol. 2014; 5:592.

PMID: 25477881 PMC: 4235267. DOI: 10.3389/fimmu.2014.00592.


Greater expression of the human leukocyte antigen-G (HLA-G) and interleukin-17 (IL-17) in cervical intraepithelial neoplasia: analytical cross-sectional study.

Miranda L, Reginaldo F, Souza D, Soares C, Silva T, Rocha K Sao Paulo Med J. 2014; 133(4):336-42.

PMID: 25351636 PMC: 10876348. DOI: 10.1590/1516-3180.2013.7170009.

References
1.
Szalmas A, Konya J . Epigenetic alterations in cervical carcinogenesis. Semin Cancer Biol. 2009; 19(3):144-52. DOI: 10.1016/j.semcancer.2009.02.011. View

2.
Burgers W, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F . Viral oncoproteins target the DNA methyltransferases. Oncogene. 2006; 26(11):1650-5. PMC: 3350866. DOI: 10.1038/sj.onc.1209950. View

3.
Zhu C, Wang C, Zhang X, Zhang J, Li W . Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer. 2010; 128(3):617-22. DOI: 10.1002/ijc.25372. View

4.
Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella E . Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol. 2007; 17(6):413-21. DOI: 10.1016/j.semcancer.2007.07.003. View

5.
Paul P, Rouas-Freiss N, Moreau P, Riteau B, Le Gal F, Avril M . HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998; 95(8):4510-5. PMC: 22520. DOI: 10.1073/pnas.95.8.4510. View